An eight-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2011
At a glance
- Drugs Aliskiren (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 07 Nov 2011 Actual initiation date changed from Jun 2006 to Jun 2005 as reported by ClinicalTrials.gov.
- 16 Mar 2007 New trial record.